Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CANbridge Pharmaceuticals Inc. ( (HK:1228) ) has provided an announcement.
CANbridge Pharmaceuticals Inc. has announced a proposal to refresh its Existing General Mandate, allowing directors to issue new shares up to 20% of the company’s issued share capital. This move comes after the full utilization of the existing mandate, and aims to provide the company with greater flexibility in managing its capital structure, potentially impacting its market positioning and offering new opportunities for investment.
The most recent analyst rating on (HK:1228) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on CANbridge Pharmaceuticals Inc. stock, see the HK:1228 Stock Forecast page.
More about CANbridge Pharmaceuticals Inc.
CANbridge Pharmaceuticals Inc. is a biopharmaceutical company incorporated in the Cayman Islands, focusing on the development and commercialization of therapies for rare diseases and targeted cancers. The company is listed on the Hong Kong Stock Exchange.
Average Trading Volume: 5,927,262
Technical Sentiment Signal: Buy
Current Market Cap: HK$955.2M
For detailed information about 1228 stock, go to TipRanks’ Stock Analysis page.